RxDoctor Payments Data

Cynthia Michel Knowles, DO

Internal Medicine · Plantation, FLNPI 1912991498

Payments from drug & device makers

$1,901in general payments, 2019–2025

Across 25 payments — averaging $76.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Novo Nordisk$248
  • AstraZeneca$202
  • Lilly USA, LLC$183
  • Exact Sciences$95
  • Gilead$30
  • plus $84 from 4 others

What the payments were for

  • Travel & lodging$73339%
  • Food & beverage$1,13560%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,901 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$38,569
Medicare patients
154
Services billed
407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$50,750
Breo ElliptaFluticasone/Vilanterol12$6,684
SymbicortBudesonide/Formoterol Fumarate11$4,345
SynthroidLevothyroxine Sodium46$3,754
Rosuvastatin Calcium252$3,265
Atorvastatin Calcium336$2,735
Amlodipine Besylate398$2,364
Ezetimibe66$2,329
Levothyroxine Sodium241$2,161
Losartan Potassium209$1,883
Omeprazole98$1,711
Albuterol Sulfate HfaAlbuterol Sulfate66$1,458
Metformin Hcl252$1,299
Fluticasone Propionate81$1,233
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide109$1,122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$248$50,75051 claims
GSKBreo Ellipta$21$6,68412 claims
AstraZenecaSymbicort$202$4,34511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Plantation

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →